NCT01599962

Brief Summary

To investigate the effects of the calcimimetic agent cinacalcet on cognitive functions in healthy humans.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Mar 2012

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2012

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

May 2, 2012

Completed
14 days until next milestone

First Posted

Study publicly available on registry

May 16, 2012

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2012

Completed
Last Updated

October 3, 2012

Status Verified

October 1, 2012

Enrollment Period

5 months

First QC Date

May 2, 2012

Last Update Submit

October 2, 2012

Conditions

Outcome Measures

Primary Outcomes (2)

  • Change of attention functions under cinacalcet

    two study days within 10 days

  • Change of memory functions under cinacalcet

    two testing days within 10 days

Secondary Outcomes (1)

  • Change of emotional state under cinacalcet

    two study days within 10 days

Study Arms (2)

Cinacalcet

EXPERIMENTAL
Drug: Cinacalcet

Sugar pill

PLACEBO COMPARATOR
Drug: CinacalcetDrug: Placebo

Interventions

single administration, 90mg

CinacalcetSugar pill

single administration

Sugar pill

Eligibility Criteria

Age18 Years - 40 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • healthy
  • normotensive
  • native or fluent German-speaking
  • caucasian (European ancestry)
  • BMI between 19 and 27 kg/m2

You may not qualify if:

  • acute or chronic psychiatric or somatic disorder
  • pathological ECG
  • Low serum calcium
  • known hypersensitivity to the IMP
  • pregnancy
  • breast-feading
  • long-term medication within last 3 months
  • smoking more than 3 cigarettes per day
  • seizures in participants and first degree relatives
  • concurrent participation in another study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Basel, Division of Cognitive Neuroscience

Basel, Basel, 4055, Switzerland

Location

MeSH Terms

Interventions

Cinacalcet

Intervention Hierarchy (Ancestors)

NaphthalenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsPolycyclic Compounds

Study Officials

  • Dominique de Quervain, Prof. MD

    University of Basel

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Director of the Division of Cognitive Neuroscience

Study Record Dates

First Submitted

May 2, 2012

First Posted

May 16, 2012

Study Start

March 1, 2012

Primary Completion

August 1, 2012

Study Completion

August 1, 2012

Last Updated

October 3, 2012

Record last verified: 2012-10

Locations